| Annette M Schweiger Fischer, MD | |
|
2850 Se Powell Valley Rd, Gresham, OR 97080-1494 | |
| (503) 666-5050 | |
| Not Available |
| Full Name | Annette M Schweiger Fischer |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 33 Years |
| Location | 2850 Se Powell Valley Rd, Gresham, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356405690 | NPI | - | NPPES |
| 074042 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD19607 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Newberg Medical Center | Newberg, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Oregon | 0648183608 | 1328 |
News Archive
NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE Cancer Profiles based on next-generation sequencing (NGS).
A vaginal ring intended to be used for a month at a time has moved one step closer to potentially becoming a new HIV prevention method for cisgender women in sub-Saharan Africa, who despite being the face of the epidemic, have few options for protecting themselves against getting infected.
A.D.A.M., Inc., a leading provider of innovative online technology solutions for the health, benefits and education markets, today announced that its shareholders have approved the Agreement and Plan of Merger, dated as of August 29, 2010, by and among A.D.A.M., Ebix, Inc. ("Ebix") and Eden Acquisition Sub, Inc., a direct wholly owned subsidiary of Ebix.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3). Fenwal's InterSol® solution was approved by the FDA in December 2009 under a new drug application. It is the first and only platelet additive solution now available in America.
› Verified 4 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023488343 PECOS PAC ID: 0648183608 Enrollment ID: O20031106000652 |
News Archive
NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE Cancer Profiles based on next-generation sequencing (NGS).
A vaginal ring intended to be used for a month at a time has moved one step closer to potentially becoming a new HIV prevention method for cisgender women in sub-Saharan Africa, who despite being the face of the epidemic, have few options for protecting themselves against getting infected.
A.D.A.M., Inc., a leading provider of innovative online technology solutions for the health, benefits and education markets, today announced that its shareholders have approved the Agreement and Plan of Merger, dated as of August 29, 2010, by and among A.D.A.M., Ebix, Inc. ("Ebix") and Eden Acquisition Sub, Inc., a direct wholly owned subsidiary of Ebix.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3). Fenwal's InterSol® solution was approved by the FDA in December 2009 under a new drug application. It is the first and only platelet additive solution now available in America.
› Verified 4 days ago
| Entity Name | Legacy Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902827272 PECOS PAC ID: 0244144004 Enrollment ID: O20031117000089 |
News Archive
NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE Cancer Profiles based on next-generation sequencing (NGS).
A vaginal ring intended to be used for a month at a time has moved one step closer to potentially becoming a new HIV prevention method for cisgender women in sub-Saharan Africa, who despite being the face of the epidemic, have few options for protecting themselves against getting infected.
A.D.A.M., Inc., a leading provider of innovative online technology solutions for the health, benefits and education markets, today announced that its shareholders have approved the Agreement and Plan of Merger, dated as of August 29, 2010, by and among A.D.A.M., Ebix, Inc. ("Ebix") and Eden Acquisition Sub, Inc., a direct wholly owned subsidiary of Ebix.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3). Fenwal's InterSol® solution was approved by the FDA in December 2009 under a new drug application. It is the first and only platelet additive solution now available in America.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Annette M Schweiger Fischer, MD Po Box 3777, Portland, OR 97208-3777 Ph: (503) 413-3900 | Annette M Schweiger Fischer, MD 2850 Se Powell Valley Rd, Gresham, OR 97080-1494 Ph: (503) 666-5050 |
News Archive
NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE Cancer Profiles based on next-generation sequencing (NGS).
A vaginal ring intended to be used for a month at a time has moved one step closer to potentially becoming a new HIV prevention method for cisgender women in sub-Saharan Africa, who despite being the face of the epidemic, have few options for protecting themselves against getting infected.
A.D.A.M., Inc., a leading provider of innovative online technology solutions for the health, benefits and education markets, today announced that its shareholders have approved the Agreement and Plan of Merger, dated as of August 29, 2010, by and among A.D.A.M., Ebix, Inc. ("Ebix") and Eden Acquisition Sub, Inc., a direct wholly owned subsidiary of Ebix.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3). Fenwal's InterSol® solution was approved by the FDA in December 2009 under a new drug application. It is the first and only platelet additive solution now available in America.
› Verified 4 days ago
Dr. Paul E Vanbredavriesman, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 18000 Se Stark Street, Gresham, OR 97233 Phone: 503-255-4243 Fax: 503-255-4243 | |
Dr. Joseph Mark Eisenberg, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 Ne 8th St, 3rd Floor, East County Health Center, Gresham, OR 97030 Phone: 503-988-5155 Fax: 503-988-5185 | |
Gordon Paul Canzler, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 Ne Roberts Ave, Gresham, OR 97030 Phone: 503-665-9144 Fax: 503-665-6404 | |
Janet R Monnier, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 831 Nw Council Dr, Suite 101, Gresham, OR 97030 Phone: 503-665-8176 Fax: 503-665-8178 | |
Caroline Chase Adams, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 440 Nw Division St, Gresham, OR 97030 Phone: 503-215-9525 | |
Paul Podett, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 24900 Se Stark St Ste 205, Gresham, OR 97030 Phone: 503-665-1010 Fax: 503-665-1023 | |
Svetlana Taycher, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 831 Nw Council Dr, Suite 125, Gresham, OR 97030 Phone: 503-661-3439 Fax: 503-669-1360 |